Photo: Courtesy of Eli Lilly

18 July 2017Americas

Eli Lilly settles Cialis patent litigation with generic makers

Eli Lilly has entered into a settlement agreement with generic companies Teva Pharmaceuticals and Watson Laboratories to resolve pending patent litigation over its drug Cialis (tadalafil).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Eli Lilly tries to halt another Cialis generic

10 April 2018 Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.

UK Supreme Court invalidates Eli Lilly patent relating to Cialis

27 March 2019 The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

More on this story

Eli Lilly tries to halt another Cialis generic

10 April 2018 Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.

UK Supreme Court invalidates Eli Lilly patent relating to Cialis

27 March 2019 The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

More on this story

Eli Lilly tries to halt another Cialis generic

10 April 2018 Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.

UK Supreme Court invalidates Eli Lilly patent relating to Cialis

27 March 2019 The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages